⚡ Flash Summary
Highnoon Laboratories reported an increase in revenue and profit for the quarter ended September 30, 2025. The company’s revenue increased to PKR 6.90 billion compared to PKR 6.29 billion in the same quarter last year. Profit after tax rose to PKR 730.45 million from PKR 789.23 million. Despite the revenue and profit increase, the company declared no cash dividend, bonus shares or right shares, which may disappoint some investors.
📌 Key Takeaways
- 💰 Revenue increased by 9.84% to PKR 6,903.75 million for the three months ended September 30, 2025, compared to PKR 6,285.30 million in the corresponding period of 2024.
- 📈 Gross profit increased by 18.30% to PKR 3,771.96 million for the three months ended September 30, 2025, compared to PKR 3,188.04 million in the corresponding period of 2024.
- 💼 Profit from operations increased by 14.98% to PKR 1,165.31 million for the three months ended September 30, 2025, compared to PKR 1,014.16 million in the corresponding period of 2024.
- 💸 Profit before income tax and final tax increased by 13.17% to PKR 1,218.40 million for the three months ended September 30, 2025, compared to PKR 1,076.27 million in the corresponding period of 2024.
- ✅ Earnings per share (basic and diluted) increased to PKR 13.79 for the three months ended September 30, 2025, compared to PKR 14.90 in the corresponding period of 2024.
- 📊 For the nine months ended September 30, 2025, revenue from contracts with customers- net increased to PKR 20,303.54 million from PKR 18,323.93 million in 2024.
- 💹 Gross profit for the nine months ended September 30, 2025, increased to PKR 11,198.36 million from PKR 9,165.28 million in 2024.
- 📉 Profit from operations for the nine months ended September 30, 2025, increased to PKR 4,015.25 million from PKR 3,224.86 million in 2024.
- ✔️ Profit after tax for the nine months ended September 30, 2025, increased to PKR 2,680.55 million from PKR 2,395.86 million in 2024.
- 🧾 The company has authorized share capital of PKR 1,000,000,000 with issued, subscribed, and paid up share capital reserves of PKR 529,833,630.
- 🏢 Total equity increased to PKR 12,356.35 million as of September 30, 2025, compared to PKR 11,795.13 million as of December 31, 2024.
- 🏦 Total assets increased to PKR 18,054.41 million as of September 30, 2025, compared to PKR 17,230.96 million as of December 31, 2024.
- 🚫 No cash dividend, bonus shares, or right shares were recommended by the Board of Directors for this quarter.
🎯 Investment Thesis
HOLD. Highnoon Laboratories shows positive financial performance with increased revenue and profit. However, the absence of dividends and potential market risks suggest a cautious approach. A HOLD recommendation is appropriate until further information on the company’s future plans and market conditions is available.
Disclaimer: AI-generated analysis. Not financial advice.